Article
Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jun 2010
Kawahara Akihiko, Yamamoto Chizuko, Nakashima Kazutaka, Azuma Koichi, Hattori Satoshi, Kashihara Masaki, Aizawa Hisamichi, Basaki Yuji, Kuwano Michihiko, Kage Masayoshi, Mitsudomi Tetsuya, Ono Mayumi
Abstract excerpt
PURPOSE: Therapeutic responses of non-small cell lung carcinoma (NSCLC) to epidermal growth factor receptor (EGFR)-targeted drugs, such as gefitinib and erlotinib, are closely associated with activating EGFR mutations. The most common mutations are delE746-A750 in exon 19 and L858R in exon 21, accounting for approximately 90% of all EGFR mutations. Recently, EGFR mutation-specific antibodies were developed and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.